Navigation Links
AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:10/1/2008

QUEBEC CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's second efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate, with its flagship product candidate, cetrorelix, a Luteinizing Hormone Releasing Hormone (LHRH) antagonist. This second efficacy study involves approximately 400 patients, mainly in Europe.

"We are very pleased to have completed patient recruitment for this second efficacy trial as scheduled. Our Phase 3 program is progressing well and remains on track with first results expected for the third quarter of 2009," said Paul Blake MD, Senior Vice President and Chief Medical Officer of AEterna Zentaris. "We firmly believe that cetrorelix's novel therapeutic approach could lead to a more efficacious and convenient treatment for the millions of men with BPH."

The study, titled, "Cetrorelix pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This Phase 3 trial, conducted in Europe under the supervision of lead investigator, Prof. Dr. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, is part of the Company's Phase 3 program with cetrorelix being studied in approximately 1,500 patients in North America and Europe in men with symptomatic BPH.

About the Phase 3 Program with Cetrorelix in BP
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
2. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
3. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
4. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
5. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
6. AEterna Zentaris Sells Quebec City Building for $7.1 million
7. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
8. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
9. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
10. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
11. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders ... Clinical Lab Expo in Chicago ... diagnostic research and technology that will advance medicine and ... of Wednesday, July 30, more than 19,500 attendees had ... Lab Expo, with more than 10,000 of these attendees ...
(Date:7/31/2014)... the sound-processing part of the mouse brain in a ... trees in view. Their imaging technique allows zooming in ... and it enabled the team to watch brain cells ... results, which represent a step toward better understanding how ... the journal Neuron . , In the past, ...
(Date:7/31/2014)... Calif. , July 31, 2014 Rogne ... San Francisco Bay Area , has acquired a ... of Oxford,s commercialisation company. The potent anti-inflammatory activity of ... at the University of Oxford,s Sir William ... company, which has raised over $1.5 million in seed ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... New England Biolabs has expanded its line of PCR reagents ... Start DNA Polymerases. Optimized blends of Taq and ... robust amplification across a wide range of templates, including routine, ... Vent increases the fidelity and robustness of Taq , ...
... 2011 QPS Holdings, LLC, a leading full-service ... support preclinical and clinical research and development, announced ... Preclinical Sciences (CTPS) from Taiwan,s Development Center for ... a division of QPS-Taiwan. QPS is ...
... Inc., a pharmaceutical company developing orally-available broad spectrum ... $45 million Series F financing. New Leaf Venture ... investors Pappas Ventures and Morningside Group, as well ... Partners, Asset Management Company and Frazier Healthcare Ventures. ...
Cached Biology Technology:New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan 2Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 2Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 3Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 4
(Date:7/31/2014)... adipocytes, or fat cells, are inherently different. Each of ... its own role in metabolism. In the human body, ... Its primary function is energy storage. On the other ... but are only found in a few places in ... special type of brown adipocytes, appear mixed with brown ...
(Date:7/30/2014)... the way for a breakthrough that may prevent ... to poisonous chemicalsparticularly those in pesticides and chemical ... issue of the journal ChemBioChem outlines ... commonly used in pesticides and warfare agents. The ... Engineering Associate Professor of Chemical and Biological Engineering ...
(Date:7/30/2014)... the potential effects of climate change on the ... the wrong factors, according to a new paper ... Society, University of Queensland, and other organizations. The ... is missing the point when it comes to ... climate change scientists focus on the "direct" threats ...
Breaking Biology News(10 mins):Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... This release is available in German . ... Zentrum Mnchen, the German Center for Neurodegenerative Diseases (DZNE) and ... have now discovered that lipid peroxides* play a specific physiological ... already established that accumulation of lipid peroxides* indicate cell stress. ...
... new study shows that male rats prenatally exposed to low ... to develop prostate inflammation and to go through puberty later ... of literature on atrazine, an herbicide predominantly used to control ... cane. Atrazine and its byproducts are known to be relatively ...
... a half billion years ago, Earth differed greatly from ... of gases in the atmosphere and the nature of ... consists of about 21 percent oxygen, the ancient atmosphere ... organisms. The complex eukaryotic life we are familiar with ...
Cached Biology News:Lipid peroxides -- more sophisticated than their reputation 2Atrazine causes prostate inflammation in male rats and delays puberty 2Ancient microbes responsible for breathing life into ocean 'deserts' 2Ancient microbes responsible for breathing life into ocean 'deserts' 3Ancient microbes responsible for breathing life into ocean 'deserts' 4
... contains sufficient materials for 1,464 array sample elements. ... , Blocker BSA in PBS (10X): ... HRP-conjugated: 10 g , BupH Phosphate ... Tween-20: 2 x 10 ml ampules , SuperSignal ...
... The Partec Cell Counter Analyser counts ... that the CCA detects only cells, so ... influence the results.,While passing through a 250 ... a fluorescence light signal which is used ...
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Results Laser Capture Microdissection (LCM) enables ... accuracy of molecular assays by starting with ... structures isolated from whole tissue or cytology ... 1996 at the National Institutes of Health ...
Biology Products: